This clinical trial is focused on studying treatments for non-small cell lung cancer (NSCLC), specifically for patients with Stage III cancer that cannot be surgically removed. The study will compare two different treatment approaches. One group of participants will receive a combination of MK-7684A (a coformulation of vibostolimab and pembrolizumab) along with radiation and chemotherapy. The other group will receive radiation and chemotherapy followed by durvalumab. The purpose of the study is to evaluate the effectiveness of these treatments in improving progression-free survival and overall survival.

Participants in the study will undergo a series of treatments over a period of time. The treatments will be administered through intravenous infusion, which means the medication is given directly into a vein. The study will involve regular monitoring and assessments to track the progress of the disease and the response to the treatment. This will help researchers understand how well the treatments work and their impact on the participants’ health and quality of life.

The study aims to provide valuable insights into the treatment of non-small cell lung cancer and potentially improve outcomes for patients with this condition. By comparing the two treatment approaches, researchers hope to determine which method is more effective in managing the disease and extending the lives of those affected by it. Participants will be closely monitored throughout the study to ensure their safety and well-being.